Mobile

A trial to assess the safety, tolerability and immunogenicity of Repevax® and rLP2086 vaccine when given together in healthy subjects aged ≥11 to <19 years

Update Il y a 4 ans
Reference: EUCTR2010-022449-38

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate that the immune response induced by Repevax given with the bivalent rLP2086 vaccine (group 1) is non-inferior to the immune response induced by Repevax alone (group 2) when measured 1 month after vaccination 1. The immune responses to all components of Repevax will be assessed.

Inclusion criteria

  • Healthy volunteers (prevention of bacterial meningitis)

Links